Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Combined With Local Chest Radiotherapy in EGFR+ NSCLC With Malignant Pleural Effusion
NCT07482605Phase 2Not yet recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), malignant pleural effusion (MPE), sponsored by Jiangmen Central Hospital. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT07482605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07482605.